Phase 2 N=28 Sutent + Taxol for Advanced Esophageal Cancer
Esophageal Cancer
Primary: Progression Free Survival Rate at 24 Weeks — 25 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Neuroblastoma
Primary: Maximum Tolerated Dose — 18.6 mCi/kg
Phase 2 N=17 Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Disease-free Survival-incidence of Survival Without Relapse — 47 percentage of participants
Phase 2 N=60 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Evaluate the Risk of Transplant Related Mortality. — 20 percentage of participants
Phase 2 N=26 Transcranial Direct Stimulation in Chronic Pelvic Pain
Pelvic Pain · Healthy
Primary: Pain Assessment — -2.375; -1.625 units on a scale
Phase 2 N=35 Pazopanib in Treating Patients With Recurrent Glioblastoma
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: 6 Months Progression-free Survival — 3 percent
Phase 2 N=41 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
Recurrent Thyroid Gland Carcinoma · Stage III Thyroid Gland Follicular Carcinoma · Stage III Thyroid Gland Papillary Carcinoma
Primary: Progression-free Survival to Determine the 6-month Progression-free-survival (PFS) Rate — 5.4 months
Phase 2 N=82 Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
Esophageal Cancer
Primary: Proportion of Patients With Adenocarcinoma Achieving a Pathologic Complete Response (CR) After Surgery — 19 percentage of participants
Phase 2 N=149 Early Versus Delayed BCG Vaccination of HIV-exposed Infants
HIV Exposure · HIV Infection
Primary: T Cell Activation — 1.8; 1.3 percentage of CD4+ T cells
Phase 2 N=16 Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Completing Treatment in Study TL7116958
Asthma and Rhinitis
Primary: Mean Change From Baseline in the Total Nasal Sym. Score (TNSS) at Post-NAC 15 Minutes (Min) — 3.8; 5.9 Score on a scale
Phase 2 N=16 Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver
Hepatitis B · Liver Transplantation
Primary: Development of de Novo Hepatitis B Infection After Transplant With a Core Antibody Positive Liver — 5 Participants
Phase 2 N=245 Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Esophageal Cancer
Primary: Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma — 61; 45; 54 percentage of participants
Phase 2 N=38 Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
Graft Versus Host Disease
Primary: Response Rate — 20 percentage of participants
Phase 2 N=35 Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS) · Chronic Myelomonocytic Leukemia (CMML)
Primary: Overall International Working Group (IWG) 2006 Response Rate — 0; 2; 19; 14 Participants
Phase 2 N=24 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Determine the Overall Response Rate (ORR), Including Complete Responses (CR) and Partial Responses (PR) — 16.7 percentage of patients